A NEW study has identified soluble α2δ-1 as a key extracellular regulator of brain network stability, with findings suggesting potential therapeutic relevance for schizophrenia.
Excitation–inhibition (E/I) balance is essential for coordinated brain activity, enabling precise communication between excitatory and inhibitory neurons. Disruption of this balance is a hallmark of neuropsychiatric disorders such as schizophrenia, contributing to cognitive deficits and altered social behaviour. While most research has focused on synaptic transmission, emerging evidence suggests that extracellular signalling molecules may also play a critical role in maintaining network homeostasis.
Network Homeostasis in Schizophrenia
Researchers identified a soluble form of the voltage-gated calcium channel subunit α2δ-1 in human cerebrospinal fluid, demonstrating that it functions as an activity-regulated extracellular modulator of neuronal network homeostasis. Levels of soluble α2δ-1 were reduced in the cerebrospinal fluid of individuals with schizophrenia, indicating a potential association with disease-related network dysfunction.
To explore its functional role, the team developed a synthetic analogue, termed SEAD1 (synthetic ectodomain of α2δ-1). In experimental models, SEAD1 modulated cortical network activity and enhanced the function of parvalbumin-positive interneurons, a key neuronal subtype involved in maintaining E/I balance.
Soluble α2δ-1 Analogue Restores Brain Function
The functional impact of this pathway was demonstrated in a genetic mouse model of schizophrenia. A single administration of SEAD1 into the prefrontal cortex restored disrupted E/I balance and improved synaptic function.
These physiological changes translated into measurable behavioural improvements, with treated mice showing recovery in memory performance and social interaction deficits, two features commonly associated with schizophrenia.
Future Directions
The findings highlight soluble α2δ-1 as part of a previously underappreciated class of extracellular signalling molecules that extend beyond traditional neurotransmission. By influencing neuronal networks at a systems level, these molecules may offer new opportunities for therapeutic intervention.
However, the study was conducted in preclinical models, and further research is required to determine whether these effects translate to humans. Key questions remain regarding long-term safety, delivery strategies, and whether modulation of this pathway could benefit a broader range of neuropsychiatric conditions.
If validated in future studies, targeting soluble α2δ-1 signalling may represent a novel approach to restoring brain network balance in disorders characterised by circuit dysfunction.
Reference
Dos Santos M et al. Soluble α2δ-1, altered in disease CSF, modulates network homeostasis and rescues deficits in a neuropsychiatric mouse model. Neuron. 2026;DOI:10.1016/j.neuron.2026.02.004.
Featured image: lumerb on Adobe Stock
